Blog Single

Executive Summary: Electronic health record and health IT software companies are typically valued less like traditional service businesses and more like recurring revenue software platforms. Buyers focus on annual recurring revenue (ARR), net revenue retention (NRR), implementation stickiness, and switching costs because these factors indicate how durable future cash flow will be. For Atlanta business owners in healthcare IT, understanding these metrics is critical when preparing for a sale, recapitalization, or strategic growth event, because they often explain why two companies with similar EBITDA can command very different valuation multiples.

Introduction

EHR and health IT software valuation requires a different lens than the one used for a conventional operating company. In many cases, the market values these businesses primarily on the quality and predictability of recurring revenue rather than on current earnings alone. That distinction matters because a software company with modest EBITDA today may still warrant a premium multiple if it has strong ARR growth, low churn, high implementation friction, and a sticky customer base.

For owners, buyers, and advisors, the key question is not simply how much revenue the company generated last year. It is how much of that revenue is recurring, how much will renew, how much will expand, and how defensible the business is against replacement. In a healthcare software environment, where workflows are deeply embedded into provider operations, those answers often drive value more than headline profitability.

At Atlanta Business Valuations, we regularly evaluate companies in software, healthcare services, and technology-enabled recurring revenue sectors. For Atlanta founders in Midtown, Buckhead, Alpharetta, or the broader healthcare IT corridor, these valuation concepts are especially relevant because regional buyer interest remains strong for firms that have recurring contracts, specialized vertical expertise, and scaleable implementation processes.

Why This Metric Matters to Investors and Buyers

Investors and strategic buyers focus on ARR because it provides a clean measure of committed future revenue. Unlike one-time project income, ARR reflects contractually recurring subscription fees and support revenue that can be counted on, subject to normal churn and expansion trends. In the EHR and health IT segment, ARR often includes license subscriptions, maintenance fees, platform access charges, and support contracts, although buyers will scrutinize what portion is truly recurring versus one-time implementation work.

NRR is equally important because it shows whether the existing customer base is growing after accounting for churn. A company with 115 percent NRR is generally outperforming one with 90 percent NRR, even if both report the same current-year revenue. High NRR signals strong product adoption, upsell potential, and customer satisfaction. It also reduces the need for constant new customer acquisition merely to replace lost revenue. In valuation terms, that usually supports a higher ARR multiple and a stronger DCF outcome.

Implementation stickiness is another core driver. EHR systems are rarely swapped casually. Once a hospital, physician group, or specialty clinic has migrated data, trained staff, integrated billing, and connected interfaces, replacement becomes costly and disruptive. This stickiness creates a practical moat. Buyers pay for that moat because it lowers churn risk and improves the visibility of future cash flow. In a sector where switching may require retraining clinicians, reconfiguring templates, and managing compliance risk, embedded systems tend to have better pricing power and more resilient margins.

For acquirers, these factors can justify premium multiples that exceed general software averages, particularly when the company serves a niche with regulatory complexity, high integration requirements, or mission-critical workflows. That is why a disciplined valuation must assess not only revenue size, but also retention quality, contract structure, and customer dependency.

Key Valuation Methodology and Calculations

ARR as the Primary Valuation Anchor

In many software transactions, ARR becomes the starting point for valuation. Revenue multiples are often applied to recurring revenue rather than total revenue because recurring revenue is more predictable and easier to underwrite. For EHR and health IT companies, ARR multiples can vary widely based on growth rate, customer concentration, gross margin, and product maturity. A slower-growing mature platform may trade in a lower range, while a high-growth vertical SaaS business with strong retention can trade at a materially higher multiple.

As a practical matter, a buyer may compare the target to public software comparables, relevant precedent transactions, and internal return benchmarks. If the company grows ARR at 15 percent to 25 percent annually, maintains gross margins above 70 percent, and has churn below industry norms, the market may support a stronger multiple than for a similar business with flat growth and inconsistent renewals.

The Importance of NRR in Multiple Selection

NRR measures the percentage of recurring revenue retained and expanded from the same customer base over a defined period, usually 12 months. A company at 100 percent NRR is replacing lost revenue exactly. Above 100 percent, the business is expanding within the base. In software valuation, NRR in the range of 110 percent to 130 percent is often viewed favorably, especially if supported by durable product adoption rather than temporary price increases.

A strong NRR profile helps reduce perceived risk in a discounted cash flow model by improving forecast confidence. It also supports a higher EBITDA multiple because future revenue growth does not rely solely on new logo acquisition. If the company can consistently expand account value through add-on modules, workflow automation, analytics, or premium support, buyers may view the platform as more than a basic software vendor. They may see it as an embedded operating system for the customer’s clinical or administrative process.

Implementation Stickiness and Switching Costs

Implementation stickiness is the practical reason software revenue becomes dependable. In EHR environments, the onboarding process can take months and involve workflow mapping, data migration, training, interface development, HIPAA-related controls, and operational change management. These switching costs are not just financial. They are also procedural, legal, and cultural.

From a valuation perspective, high switching costs reduce attrition risk and protect long-term margins. Buyers often reward that protection with premium valuation assumptions because the business behaves more like an annuity than a one-time project vendor. In due diligence, acquirers will ask how difficult it would be for a customer to leave, what percentage of clients have multi-year contracts, whether data interoperability is proprietary, and how deeply the platform is integrated into daily operations.

The stronger these barriers, the more defensible the valuation. In some cases, those moats can also affect the discount rate in a DCF model by reducing the risk premium applied to projected cash flows.

How DCF and EBITDA Multiples Fit Together

Although ARR is central, it does not replace traditional valuation methods. A proper analysis still considers EBITDA multiples and discounted cash flow. EBITDA is especially useful when the business has normalized margins and a stable customer base. However, in higher-growth software companies, current EBITDA may understate enterprise value because management is reinvesting heavily in product development, sales, and implementation infrastructure.

A DCF analysis can capture the long-term value of recurring revenue expansion, especially when cash flows are expected to improve as implementation costs are absorbed and churn remains low. Meanwhile, EBITDA multiples provide a market-based reference point for what sophisticated buyers may pay today. The best valuation conclusion often comes from triangulating ARR multiples, EBITDA multiples, and DCF output, then adjusting for customer concentration, regulatory exposure, and the quality of revenue recurrence.

As an example, two EHR companies may each generate $5 million of EBITDA. If one has 120 percent NRR, low churn, and 85 percent ARR visibility, while the other depends on one-time setup projects and has declining renewals, the first company may command a materially higher enterprise value. The market is not simply paying for earnings, it is paying for the durability and scalability of those earnings.

Atlanta Market Context

Atlanta has become a meaningful hub for healthcare IT, software development, and data-driven services, with activity extending through Midtown, Buckhead, Alpharetta, and the Atlanta Tech Village corridor. That local concentration matters because strategic buyers and private equity firms often look to metro Atlanta for software businesses with specialized industry focus, technical talent, and access to healthcare customers across the Southeast.

Regional deal activity is also influenced by the broader Southeast market, where providers and operators increasingly seek digital tools that improve efficiency, compliance, and reimbursement performance. For an Atlanta-based EHR or health IT company, proximity to major hospital systems, outpatient groups, and payer-adjacent organizations can support commercial relationships that strengthen recurring revenue quality.

Georgia-specific considerations can also affect transaction structure and post-sale planning. Georgia’s single-factor apportionment regime for corporate income tax can influence how multi-state software businesses think about nexus and tax exposure. In some situations, Opportunity Zone implications may also be relevant for owners evaluating reinvestment decisions. While Georgia capital gains treatment should be reviewed carefully with tax advisors, sale proceeds from a software company can raise planning issues that affect after-tax value just as much as gross enterprise value. These factors may not change the headline valuation multiple, but they absolutely affect the economics of the transaction.

Common Mistakes or Misconceptions

One common mistake is assuming that all software revenue should be valued the same way. Not all recurring revenue is equal. A short-term contract with weak adoption and heavy cancellation risk should not receive the same multiple as a deeply embedded platform with multi-year renewals and expansion revenue.

Another error is overemphasizing top-line growth without examining retention quality. Rapid acquisition can mask churn. A company growing ARR at a fast pace but losing customers almost as quickly may look strong at first glance, yet still produce a discounted valuation once churn is normalized.

Some owners also underestimate the value of implementation complexity. They may treat onboarding as a burden, while buyers see it as a moat. If implementation creates switching friction, data dependency, and workflow inertia, it can materially increase the defensibility of the business. The key is whether that friction is internally manageable and commercially valuable, not simply operationally inconvenient.

Finally, sellers often forget that valuation is not determined by one metric in isolation. A buyer will assess ARR, NRR, gross margin, backlog, customer concentration, sales efficiency, and founder dependency together. In an Atlanta middle-market transaction, that holistic view can be the difference between a standard software multiple and a premium outcome.

Conclusion

EHR and health IT software companies are valued on the strength and quality of their recurring revenue engine. ARR provides the base, NRR shows whether the base is expanding, implementation stickiness explains why the revenue persists, and switching costs help justify premium multiples. When those elements align, the business may trade at a valuation that exceeds what EBITDA alone would suggest.

For Atlanta business owners, especially those operating in healthcare IT, understanding these drivers is essential before pursuing a sale, bringing in growth capital, or planning a partner buyout. A well-supported valuation should reflect both the financial statements and the strategic value of embedded software relationships, regulatory complexity, and long-term retention economics.

If you own an EHR or health IT software company in Atlanta or the surrounding market, Atlanta Business Valuations can provide a confidential, professional valuation consultation tailored to your specific business, growth profile, and transaction goals. Visit https://atlantabusinessvaluations.com/ to schedule a discussion with our team.